Medicus Pharma Ltd (MDCX) AI Stock Analysis

• Market Cap: $28.88M
• Dividend Yield: N/A
• Average Volume (3M): 264.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.34
• Revenue Growth: N/A
• EPS Growth: -55.95%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.12
• Shares Outstanding: 25,114,143
• 10 Day Avg. Volume: 348,975
• 30 Day Avg. Volume: 264,290
• PEG Ratio: 0.07
• Price to Book (P/B): 7.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.28
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.65
• 1Y Price Target: $12.00
• Price Target Upside: 721.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.78
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $1.00 ▼(-31.51% Downside)

The score is held down primarily by weak financial performance (no revenue, widening losses, heavy cash burn, and negative equity), alongside bearish technicals (price below major moving averages and negative MACD). Corporate events provide some support via additional financing and pipeline activity, but potential dilution and ongoing losses keep the overall outlook constrained; valuation inputs are limited due to negative earnings.

Positive Factors

Teverelix Phase 1 clinical profile

Robust Phase 1 pharmacodynamics and a favorable safety profile reduce clinical development risk for Teverelix. Sustained hormone suppression and evidence of clinically relevant estradiol control support differentiated, long-acting positioning versus competitors and improve odds of successful later-stage trials or partnering.

License amendment lowers royalty burden

A permanent cut in royalty rate materially improves potential net economics if Teverelix reaches market. Lower royalties increase long-term product margin and attractiveness to partners/licensees, strengthening commercial incentive and preserving more proceeds for reinvestment in pipeline expansion and commercialization.

Formal equity program provides funding flexibility

An established ATM facility gives disciplined, on-demand access to equity capital to support multi-stage clinical programs. This structural funding flexibility helps sustain development cadence, avoids single large dilutive events if used opportunistically, and underpins continuation of near-term trials.

Negative Factors

Pre-revenue with widening net losses

Absence of product revenue alongside materially larger net losses erodes internal funding capacity and prevents operating leverage. Over the medium term, sustained negative earnings mean the firm must repeatedly access capital markets, increasing execution risk and dependence on external financiers for survival.

Heavy and accelerating cash burn

A near-doubling of operating cash outflows compresses runway and forces more frequent financings. Persistently negative free cash flow limits strategic optionality, risks delaying trials if funding gaps emerge, and raises dilution risk, which can hinder long-term program execution and partner negotiations.

Negative shareholders' equity and funding risk

Negative equity signals capital erosion and reduces financial flexibility: it can complicate borrowing, increase cost of capital, and weaken negotiating leverage with partners. Structurally, this elevates default and dilution risk, making sustained investment in R&D and commercialization more precarious.

Medicus Pharma Ltd Business Overview & Revenue Model

Company Description

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.

How the Company Makes Money

Medicus Pharma Ltd makes money primarily through the sale of its pharmaceutical products and therapies to healthcare providers, hospitals, and pharmacies. The company generates revenue through direct sales, licensing agreements, and strategic partnerships with other pharmaceutical and biotech companies. Additionally, Medicus Pharma Ltd invests in research and development to discover new treatments, which can lead to new revenue streams through patents and proprietary products. Collaboration with research institutions and participation in clinical trials also contribute to its earnings. By maintaining a robust pipeline of innovative drugs and expanding its market presence, the company aims to sustain and grow its revenue base.

Medicus Pharma Ltd Financial Statement Overview

Summary

Pre-revenue with materially widening losses (TTM net loss about -$29.5M) and worsening cash burn (TTM operating cash flow about -$19.3M). Despite low absolute debt, equity turning negative in TTM reduces financial flexibility and increases financing/dilution risk.

Income Statement

The company reports no revenue across the annual periods shown and in TTM (Trailing-Twelve-Months), consistent with a pre-commercial biotech profile. Losses have widened meaningfully: net loss increased from about -$11.2M (2024) to about -$29.5M in TTM, with EBIT also deteriorating (from about -$11.2M to about -$20.2M). With no revenue base and accelerating losses, profitability and operating leverage remain key weaknesses despite the industry’s typical R&D-heavy model.

Balance Sheet

Leverage is modest in absolute terms (total debt about $0.24M in TTM and ~$0.32M in 2024), but the capital structure has weakened sharply as equity turned negative in TTM (from ~$3.13M positive in 2024 to about -$0.91M). Total assets increased (to about $10.0M in TTM from ~$5.6M in 2024), but negative equity reduces financial flexibility and can raise funding risk even with relatively low stated debt.

Cash Flow

Cash burn is heavy and worsening: operating cash flow declined from about -$10.2M (2024) to about -$19.3M in TTM (Trailing-Twelve-Months), and free cash flow is similarly negative (about -$19.3M in TTM). While TTM free cash flow growth is positive versus the prior period provided, the business still requires ongoing external funding to sustain operations, and the increasing burn rate is the primary concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-28.58M	-11.16M	-586.78K	-1.17M	-1.94M
Net Income	-29.53M	-11.16M	-5.31M	-1.69M	-2.06M
Balance Sheet
Total Assets	9.98M	5.65M	1.89M	282.65K	78.51K
Cash, Cash Equivalents and Short-Term Investments	8.66M	4.16M	1.72M	267.65K	78.51K
Total Debt	236.26K	322.27K	0.00	1.53M	667.93K
Total Liabilities	10.78M	2.51M	781.61K	12.48M	10.58M
Stockholders Equity	-910.13K	3.13M	1.11M	-12.20M	-10.51M
Cash Flow
Free Cash Flow	-19.29M	-10.25M	-4.16M	-1.06M	-1.45M
Operating Cash Flow	-19.29M	-10.25M	-4.16M	-1.06M	-1.45M
Investing Cash Flow	-4.69M	0.00	0.00	0.00	0.00
Financing Cash Flow	27.27M	12.69M	5.61M	1.25M	882.38K

Medicus Pharma Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDCX, the sentiment is Negative. The current price of 1.46 is above the 20-day moving average (MA) of 1.32, below the 50-day MA of 1.60, and below the 200-day MA of 2.63, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 25.13 is Positive, neither overbought nor oversold. The STOCH value of 21.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDCX.

Medicus Pharma Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JSPR	52 Neutral	$38.62M	-0.22	-191.12%	―	―	-24.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OVID	47 Neutral	$192.67M	-2.84	-60.06%	―	946.61%	-11.30%
CGTX	47 Neutral	$90.92M	-2.10	-109.73%	―	―	50.39%
PEPG	47 Neutral	$337.55M	-1.51	-62.25%	―	―	4.71%
MDCX	45 Neutral	$28.88M	―	-2237.54%	―	―	-55.95%
NRSN	44 Neutral	$26.67M	-1.49	―	―	―	31.09%

Medicus Pharma Ltd Corporate Events

Medicus Pharma Launches At-the-Market Equity Offering Program

On December 29, 2025, Medicus Pharma Ltd. entered into an Equity Distribution Agreement with Maxim Group LLC and Yorkville Securities, LLC to establish an at-the-market equity program allowing the company to issue and sell up to $15.35 million of its common shares from time to time through these firms as sales agents on Nasdaq or other permitted methods. The arrangement provides Medicus Pharma with flexible, as-needed access to equity financing, though the company is under no obligation to sell any shares, and any offering will depend on the effectiveness of its Form S-3 registration statement with the SEC, potentially affecting share dilution and capital structure depending on how much of the program is ultimately utilized.

The most recent analyst rating on (MDCX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.

Medicus Pharma’s Warrant Inducement Agreement Announced

On December 5, 2025, Medicus Pharma Ltd. entered into a warrant inducement agreement to facilitate the exercise of existing warrants, expecting gross proceeds of approximately $5.1 million. The agreement involves issuing new unregistered warrants to purchase additional shares, with the closing anticipated around December 8, 2025. This move is part of Medicus’s broader strategy to enhance its financial position and support its ongoing clinical and development activities, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (MDCX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.

Medicus Pharma Reports Q3 Loss Amid Strategic Growth

On November 14, 2025, Medicus Pharma Ltd. announced its financial and operating results for the quarter ending September 30, 2025, alongside significant corporate updates. The company has made progress in its clinical development programs, particularly with the SkinJect platform for treating basal cell carcinoma and the acquisition of Antev Limited, which enhances its drug development pipeline. Financially, the company reported a net loss of $16 million for the third quarter, reflecting increased expenses due to accelerated clinical programs and strategic acquisitions. The company’s balance sheet remains strong with $8.7 million in cash and cash equivalents, bolstered by $10.4 million from financing transactions.

The most recent analyst rating on (MDCX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.